Relay Therapeutics Highlights Positive Zovegalisib ReDiscover Trial Data

Relay Therapeutics ( (RLAY) ) just unveiled an announcement.

On March 16, 2026, Relay Therapeutics reported Phase 1/2 ReDiscover data for its PI3Kα inhibitor zovegalisib combined with fulvestrant at the recommended Phase 3 dose of 400mg twice daily taken with food in patients with PI3Kα‑mutated, HR+/HER2‑ metastatic breast cancer. The update, based on a January 13, 2026 data cut‑off, was presented at the ESMO Targeted Anticancer Therapies Congress 2026 and focused on a heavily pre‑treated population previously exposed to CDK4/6 inhibitors and at least one endocrine therapy.

Among 57 efficacy‑evaluable patients at the 400mg BID fed dose, median progression‑free survival reached 11.1 months, with similar outcomes in kinase and non‑kinase mutation subgroups, while the confirmed objective response rate was 43% in patients with measurable disease and 52% in second‑line‑only patients. Pharmacokinetic analyses showed that the fed 400mg regimen achieved drug exposures comparable to the earlier 600mg BID fasted dose, and the combination was generally well tolerated, with mostly low‑grade, manageable adverse events and only four discontinuations, reinforcing the selection of this dose for the ongoing global Phase 3 ReDiscover‑2 trial in a population that has already received CDK4/6 inhibitors and supporting Relay’s competitive position in the PI3Kα‑targeted breast cancer space.

The most recent analyst rating on (RLAY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.

Spark’s Take on RLAY Stock

According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.

The score is held back primarily by weak financial performance (large ongoing losses and cash burn) and limited valuation support from a negative P/E and no dividend. Offsetting factors include strong technical momentum and a positive corporate catalyst from FDA Breakthrough Therapy designation.

To see Spark’s full report on RLAY stock, click here.

More about Relay Therapeutics

Relay Therapeutics, Inc., listed on Nasdaq as RLAY, is a clinical-stage small molecule precision medicine company focused on developing therapies for cancer and genetic diseases. Its lead asset, zovegalisib, is the first pan‑mutant selective PI3Kα inhibitor in clinical development and is being advanced in Phase 3 trials for HR+/HER2‑ metastatic breast cancer, as well as in studies targeting PI3Kα‑driven vascular anomalies and other indications.

Relay leverages its proprietary Dynamo platform, which combines advanced computational and experimental methods to drug previously intractable or inadequately addressed protein targets. Beyond zovegalisib, the company’s pipeline includes programs for NRAS‑driven solid tumors and Fabry disease, positioning Relay as a specialist in targeted, mutation‑driven therapies within the oncology and rare disease markets.

Average Trading Volume: 2,461,248

Technical Sentiment Signal: Buy

Current Market Cap: $1.85B

Learn more about RLAY stock on TipRanks’ Stock Analysis page.